Cite

HARVARD Citation

    Cadranel, J. et al. (2018). Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients. ERJ open research. 4 (1), p. . [Online]. 
  
Back to record